Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

Koreth, 2009, Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials, JAMA, 301, 2349, 10.1001/jama.2009.813 Oliansky, 2008, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review, Biol Blood Marrow Transplant, 14, 137, 10.1016/j.bbmt.2007.11.002 Dohner, 2010, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, 115, 453, 10.1182/blood-2009-07-235358 Rollig, 2011, Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system, J Clin Oncol, 29, 2758, 10.1200/JCO.2010.32.8500 Mrozek, 2012, Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia, J Clin Oncol, 30, 4515, 10.1200/JCO.2012.43.4738 Farag, 2011, Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission, Biol Blood Marrow Transplant, 17, 1796, 10.1016/j.bbmt.2011.06.005 Cheson, 2003, Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia, J Clin Oncol, 21, 4642, 10.1200/JCO.2003.04.036 Sorror, 2005, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, 106, 2912, 10.1182/blood-2005-05-2004 Giralt, 2009, Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research, Biol Blood Marrow Transplant, 15, 367, 10.1016/j.bbmt.2008.12.497 Cox, 1972, Regression models and life-tables, J R Stat Soc Ser B, 187 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Grimwade, 1998, The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia working parties, Blood, 92, 2322, 10.1182/blood.V92.7.2322 Slovak, 2000, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study, Blood, 96, 4075, 10.1182/blood.V96.13.4075 Byrd, 2002, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461), Blood, 100, 4325, 10.1182/blood-2002-03-0772 Oran, 2011, Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia, Biol Blood Marrow Transplant, 17, 356, 10.1016/j.bbmt.2010.05.012 Breems, 2008, Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype, J Clin Oncol, 26, 4791, 10.1200/JCO.2008.16.0259 Ferrara, 2009, FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype, Am J Hematol, 84, 532, 10.1002/ajh.21458 Whitman, 2010, FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study, Blood, 116, 3622, 10.1182/blood-2010-05-283648 Breccia, 2008, Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients, Leuk Lymph, 49, 994, 10.1080/10428190801947567 Middeke, 2014, Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation, Blood, 123, 2960, 10.1182/blood-2013-12-544957 Middeke, 2012, Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q, Blood, 120, 2521, 10.1182/blood-2012-03-417972 Rucker, 2012, TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, Blood, 119, 2114, 10.1182/blood-2011-08-375758 Bowen, 2009, TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis, Leukemia, 23, 203, 10.1038/leu.2008.173 Cornelissen, 2012, The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach, Nat Rev Clin Oncol, 9, 579, 10.1038/nrclinonc.2012.150